Data from the ADNI Cores were recently integrated to generate a model for the temporal ordering of AD biomarkers38, 46, which indicates that Aβ1–42 is the first biomarker to become abnormal, followed by changes in other AD biomarkers (CSF tau, F-18 fluorodeoxyglucose-positron emission tomography) and, lastly, the onset of clinical symptoms. Here, MAPT is linked to Alzheimer disease.